March 26, 2021
PAR-21-092 - NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3 Clinical Trial Optional)
National Institute on Drug Abuse (NIDA)
The National Institute on Drug Abuse (NIDA) will host an informational webinar to provide information and respond to questions from prospective applicants who may be interested in submitting grant applications in response to the Funding Opportunity Announcement (FOA) PAR-21-092, titled “NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3 Clinical Trial Optional).”
The purpose of the FOA is to support outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications for the treatment of Substance Use Disorders (SUDs) stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use. Eligible applicants must demonstrate the ability to develop molecules with the potential to treat SUDs and advance them in the drug development continuum. The ultimate goal of this FOA is to bring molecules closer to FDA approval.
Through this FOA, NIDA seeks to attract investigators to the mission of expanding the number and breadth of lead molecules in the pipeline for drug addiction treatment, optimizing these leads, and/or advancing them to clinical testing. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are encouraged to apply.
The webinar will take place on Friday, May 28th, 2021 at 1:00 pm Eastern Standard Time in the United States.
To join the meeting:
To join this webinar, please visit this link.
Meeting ID: 160 471 4840 Passcode: 006482
To join by phone, please dial:
+16692545252, passcode: 1604714840# US or
+16468287666 passcode: 1604714840# US
Participation in the webinar, although encouraged, is optional and is not required for the submission of an application. Advanced registration is not required. You may send questions ahead of the webinar to the Scientific/Research contact listed below.
This webinar will be recorded and a video with captioning will be available after the event upon request to Dr. Ivan Montoya at email@example.com.